JBIO

#2268
Jade Biosciences, Inc. - Common Stock
20.9 5 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
20.86
21.09
Jahresspanne
8.36
27.96
Tagesänderung
+0.53%
Monatliche Änderung
+7.33%
6 month change
+44.98%
Jahresänderung
+108.46%
Vorheriger Schlusskurs
20.8 4
Open
21.0 6
Tief
20.8 6
Hoch
21.0 9
Volumen
186
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Jade Biosciences, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Jade Biosciences, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Jade Biosciences, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Jade Biosciences, Inc. quarterly report, Q1 FY2026
10-Q

Jade Biosciences, Inc. current report, Q2 FY2023

Full document

Business Context and Reporting Period

This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Aerovate Therapeutics, Inc. (Note: The input metadata references "Jade Biosciences, Inc.", but the filing text explicitly identifies the registrant as Aerovate Therapeutics, Inc.) on June 6, 2023. The report details the voting results for director elections and the ratification of the independent auditor.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

No material financial changes are reported in this document. The primary events are the successful election of two Class II directors and the ratification of the independent accounting firm.

Guidance, Outlook, and Voting Results

Proposal 1: Election of Class II Directors
Stockholders approved the election of the following nominees to serve until the 2026 Annual Meeting:

  • Allison Dorval: 18,685,353 votes For; 366,333 votes Withheld; 2,132,996 Broker Non-Votes.
  • Joshua Resnick, M.D.: 18,169,764 votes For; 881,922 votes Withheld; 2,132,996 Broker Non-Votes.

Proposal 2: Ratification of Independent Auditor
Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.

  • Votes For: 21,184,481
  • Votes Against: 0
  • Abstain: 201
  • Broker Non-Votes: 0

Outlook and Risks: The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies.

Investor Verification Checklist

  • Verify the correct registrant name is Aerovate Therapeutics, Inc. (AVTE), not Jade Biosciences, Inc.
  • Confirm the record date for the meeting was April 14, 2023, with 24,850,842 shares outstanding.
  • Note that KPMG LLP is the appointed auditor for the fiscal year ending December 31, 2023.
  • Review the Definitive Proxy Statement filed on April 19, 2023, for detailed background on the director nominees.